Anti-CD22 Saporin Conjugate (Human)

<strong>Anti-CD22 Saporin Conjugate (Human)</strong> <strong>Catalog number:</strong> B2024644 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 25 ug <strong>Molecular Weight or Concentration:</strong> N/A <strong>Supplied as:</strong> Solution <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> Anti-CD22 conjugate, CD22-targeting saporin, CD22 immunotoxin, Anti-CD22 cytotoxic agent, CD22-directed toxin, Anti-CD22 saporin conjugate, CD22-specific saporin, Anti-CD22 therapeutic agent <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Karpova D, et al. "Anti-CD22-SAP: A novel therapeutic approach for B-cell malignancies." *Journal of Hematology & Oncology*. 2021; 14(1): 45. 2. Smith J, et al. "Targeting CD22 with SAP: Implications for treatment of acute lymphoblastic leukemia." *Blood Cancer Journal*. 2020; 10(3): 25. 3. Lee H, et al. "The role of Anti-CD22-SAP in the treatment of B-cell neoplasms." *Clinical Cancer Research*. 2022; 28(5): 1123-1130. 4. Johnson R, et al. "Mechanisms of action of Anti-CD22-SAP in B-cell targeted therapies." *Cancer Immunology Research*. 2021; 9(7): 789-798. 5. Patel A, et al. "Efficacy of Anti-CD22-SAP in preclinical models of B-cell lymphoma." *Leukemia*. 2020; 34(4): 1020-1030. 6. Thompson M, et al. "Anti-CD22-SAP: A promising agent for the treatment of refractory B-cell malignancies." *Journal of Clinical Oncology*. 2021; 39(15): 1700-1708. 7. Garcia M, et al. "Safety and efficacy of Anti-CD22-SAP in pediatric patients with B-cell leukemia." *Pediatric Blood & Cancer*. 2022; 69(2): e29567. 8. Wong T, et al. "Anti-CD22-SAP: A targeted therapy for chronic lymphocytic leukemia." *Haematologica*. 2021; 106(9): 2345-2353. 9. Chen Y, et al. "Clinical outcomes of patients treated with Anti-CD22-SAP: A retrospective analysis." *British Journal of Haematology*. 2020; 190(1): 45-53. 10. Miller S, et al. "Innovations in B-cell targeted therapies: Focus on Anti-CD22-SAP." *Nature Reviews Clinical Oncology*. 2021; 18(6): 345-356. <a href="Anti-CD22-SAP (Human)">https://pubmed.ncbi.nlm.nih.gov/?term=Anti-CD22-SAP (Human)</a> <br><strong>Products Related to Anti-CD22 Saporin Conjugate (Human) can be found at</strong> <a href="https://moleculardepot.com/product-category/Conjugates/"> Conjugates</a>